SCHEMBL21290842

SCHEMBL21290842

CC(C)CN1CCCC1(CO)CO

nearest known ligand 0.36

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.36
PIK3CD O00329 1/20 0.31
CYP2D6 P10635 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24554753 0.78 HSD11B1 (0.35) HSD11B1CYP2D6
SCHEMBL24961185 0.73 HSD11B1 (0.35) HSD11B1
SCHEMBL24841889 0.72 HSD11B1 (0.39) HSD11B1PIK3CDCYP2D6
SCHEMBL26314425 0.71 HSD11B1 (0.34) HSD11B1
SCHEMBL17382093 0.71
SCHEMBL19321656 0.69
SCHEMBL24107346 0.68 PDCD1 (0.36) HSD11B1PIK3CDCYP2D6
SCHEMBL20429130 0.68 HSD11B1 (0.37) HSD11B1
SCHEMBL21618645 0.68 HSD11B1 (0.37) HSD11B1PIK3CDCYP2D6
SCHEMBL25663997 0.68 PIK3CD (0.38) HSD11B1PIK3CDCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212155-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. 2023-07-06 US disclosed
US-20230212155-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. 2023-07-06 US disclosed
US-20210053946-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. (US) 2021-02-25 US disclosed
US-10710986-B2 PD-1/PD-L1 inhibitors GILEAD SCIENCES, INC. (US) 2020-07-14 US disclosed
US-20190270727-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. 2019-09-05 US disclosed
WO-2019160882-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. (US) 2019-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212155-A1 PD-1/PD-L1 INHIBITORS PDCD1, CD274, PDCD1LG2 HSD11B1 2234/4885PIK3CD 3024/4885CYP2D6 1710/4885
US-20210053946-A1 PD-1/PD-L1 INHIBITORS PDCD1, CD274, PDCD1LG2 HSD11B1 2234/4885PIK3CD 3024/4885CYP2D6 1710/4885
US-10710986-B2 PD-1/PD-L1 inhibitors PDCD1, CD274, PDCD1LG2 HSD11B1 2234/4885PIK3CD 3024/4885CYP2D6 1710/4885
US-20190270727-A1 PD-1/PD-L1 INHIBITORS PDCD1, CD274, PDCD1LG2 HSD11B1 2234/4885PIK3CD 3024/4885CYP2D6 1710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.